CRISPR/Cas9 mutagenesis invalidates a putative cancer dependency targeted in on-going clinical trials

eLife (2017) - Comments
pubmed: 28337968 doi: 10.7554/elife.24179 issn: 2050-084x

Ann Lin, Christopher J Giuliano, Nicole M Sayles, Jason M Sheltzer